soul trial oral semaglutide cardiovascular outcomes results 2025 (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Evaluating the Cardiovascular Benefits of

Mold and pollen are believed to be responsible for thunderstorm-induced asthma, coupled with moisture, a pressure drop, and charged particles in the air

DF is not an essential nutrient, but it plays an important part in enhancing digestive capacity and maintaining intestinal health

Restrain/Challenge Complex Regulatory Requirements and Development Costs One of the key constraints faced by the global GLP-1 drug biosimilar market is that related to complexity in the development and approval process for biosimilars

1, 3 6 Although most frequently the chest, shoulder or upper arm are involved, examples have occurred everywhere on the skin surface

Surprising Fact The weight loss drug Wegovy could lower the risk of adverse cardiovascular events by 20%, according to data from a trial shared by Novo Nordisk in August

This means your weekly dose is now given as one injection from one pen